Virginia Contract Research Organization Co., Ltd. (VCRO) has successfully prepared and submitted Phase I 505(b)2 IND package in common technical document (CTD) format to the US FDA on 02/28/2014. The Phase I clinical trials investigating the new route and dosage form on the treatment for Alzheimer’s disease has been successfully accepted by the US FDA on 03/29/2014. The accomplishment has written a new page of pharmaceutical development in Taiwan.
Congratulations! Phase I 505(b)2 IND submission in Alzheimers disease was accepted by the USA FDA (Common Technical Document (CTD)) in 28 days
Virginia Contract Research Organization Co., Ltd. (VCRO) has successfully prepared and submitted Phase I 505(b)2 IND package in common technical document (CTD) format to the US FDA on 02/28/2014. The Phase I clinical trials investigating the new route and dosage form on the treatment for Alzheimer’s disease has been successfully accepted by the US FDA…